We saw that, in the blood, MS treatments actually accelerated two cellular changes associated with physiological aging: Treatments increased absolute numbers of CD11c+ myeloid DCs (p = 0.04) and CD56+ NK cells (p = 0.005). This evidence concerns the gene ITGAX and myeloid sarcoma.